Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59–60
HOS-116524 · Präparat HOS-094447
59 ANTIGOUT MEDICINES Colchicine Not studied. Concomitant use of A reduction in colchicine dosage colchicine and darunavir co-administered or an interruption of colchicine with low dose ritonavir may increase the treatment is recommended in exposure to colchicine. patients with normal renal or (CYP3A and/ or P-gp inhibition) hepatic function if treatment with PREZISTA co-administered with low dose ritonavir is required. For patients with renal or hepatic impairment colchicine with PREZISTA co-administered with low dose ritonavir is contraindicated (see sections 4.3 and 4.4). ANTIMALARIALS Artemether/Lumefantrine artemether AUC ↓ 16% The combination of PREZISTA 80/480 mg, 6 doses at 0, artemether Cmin ↔ and artemether/lumefantrine can 8, 24, 36, 48, and artemether Cmax ↓ 18% be used without dose adjustments; 60 hours dihydroartemisinin AUC ↓ 18% however, due to the increase in dihydroartemisinin Cmin ↔ lumefantrine exposure, the dihydroartemisinin Cmax ↓ 18% combination should be used with lumefantrine AUC ↑ 175% caution. lumefantrine Cmin ↑ 126% lumefantrine Cmax ↑ 65% darunavir AUC ↔ darunavir Cmin ↓ 13% darunavir Cmax ↔ ANTIMYCOBACTERIALS Rifampicin Not studied. Rifapentine and rifampicin The combination of rifapentine and Rifapentine are strong CYP3A inducers and have PREZISTA with concomitant low been shown to cause profound decreases dose ritonavir is not recommended. in concentrations of other protease inhibitors, which can result in virological The combination of rifampicin and failure and resistance development PREZISTA with concomitant low (CYP450 enzyme induction). During dose ritonavir is contraindicated attempts to overcome the decreased (see section 4.3). exposure by increasing the dose of other protease inhibitors with low dose ritonavir, a high frequency of liver reactions was seen with rifampicin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumefantrine (HOS-114826) artemether (HOS-116383) protease (HOS-085623) colchicine (HOS-086147) rifapentine (HOS-116386) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 74158b50c5b99095b0e72f07cfddcb7308a227dde01097c23cb4f0a091942901 · Zeichen 33301–36423 im Abschnitt